Rhythm Pharmaceuticals is a late-stage biopharmaceutical company that is leading the transformation of care for people living with rare genetic disorders of obesity. Rare genetic disorders of obesity can be caused by genetic deficiencies within the melanocortin-4 receptor (MC4R) pathway, and they are characterized by early-onset, severe obesity and insatiable hunger, also known as hyperphagia. These disorders may not be sufficiently managed by diet, exercise or lifestyle changes alone. Currently, there are no approved therapies for these rare conditions. 

Founded in 2008, Rhythm is developing setmelanotide as a potential treatment for multiple rare genetic disorders of obesity. In 2020, we are seeking approval from the U.S. Food and Drug Administration (FDA) for setmelanotide to treat patients with proopiomelanocortin (POMC) deficiency obesity and leptin receptor (LEPR) deficiency obesity. Rhythm is evaluating setmelanotide in an ongoing pivotal Phase 3 trial for the treatment of obesity and hyperphagia in patients with Alström syndrome and Bardet-Biedl syndrome, and expects to announce topline data at the end of 2020 or early in 2021. Rhythm is currently assessing setmelanotide in several additional disorders in our Phase 2 Basket Study.